概括
自免疫神经系统疾病涉及免疫系统对神经系统的攻击. 本综述涵盖了免疫疗法,症状管理和对这些复杂疾病的基本护理考虑.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 神经免疫学 神经免疫学
背景情况:
- 自身免疫神经系统疾病的特点是免疫系统攻击中央,外周或自主神经系统.
- 现在有超过50种抗体与这些疾病有关,诊断能力正在迅速发展.
- 从历史上看,治疗策略一直依赖于专家意见和案例研究.
研究的目的:
- 为自身免疫神经系统疾病的急性和维持免疫疗法提供全面的信息.
- 审查症状管理和对患者护理的特殊考虑.
- 讨论不断变化的治疗方案,包括FDA批准的生物药物和正在进行的临床试验.
主要方法:
- 对免疫疗法和症状管理的当前文献的综述.
- 对最近FDA批准和正在进行的自身免疫神经系统疾病临床试验的分析.
- 讨论诊断方法和影响治疗决策的因素.
主要成果:
- 该领域在已识别的抗体和诊断工具方面出现了显著的扩张.
- 生物药物现在已获得FDA批准,用于神经炎光学谱系障碍和骨髓质疏松症.
- 临床试验正在积极研究针对自身免疫性脑炎和其他疾病的新疗法.
结论:
- 早期识别和彻底评估对于最佳的患者护理至关重要.
- 治疗需要考虑疾病的发病,免疫疗法机制和个体患者的需求.
- 综合免疫治疗和症状管理的多学科方法是必不可少的.
相关概念视频
Autoimmune Disorders
404
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
404
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172


